₹-12.75
(Market cap
₹6,282 Cr
Recently Viewed
Clear AllMarket cap
₹6,282 Cr
Revenue (TTM)
₹1,801 Cr
P/E Ratio
29.4
P/B Ratio
3
Div. Yield
0.7 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹214 Cr
ROE
14.5 %
ROCE
17.6 %
Industry P/E
49.8
EV/EBITDA
16.3
Debt to Equity
0.2
Book Value
₹230.5
EPS
₹23.8
Face value
5
Shares outstanding
90,657,751
CFO
₹754.31 Cr
EBITDA
₹1,397.71 Cr
Net Profit
₹805.03 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aarti Pharmalabs
| -7.8 | 7.7 | -12.6 | -2.7 | 24.0 | -- | -- |
|
BSE Healthcare
| 0.1 | 2.8 | 5.2 | 3.6 | 24.0 | 13.2 | 10.8 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Aarti Pharmalabs
| 7.6 | 35.8 |
|
BSE Small Cap
| -6.6 | 29.0 |
|
BSE Healthcare
| -3.3 | 43.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aarti Pharmalabs
|
694.0 | 6,282.1 | 1,800.6 | 211.2 | 17.7 | 10.7 | 29.4 | 3.0 |
| 2,423.2 | 19,833.3 | 1,215.1 | 284.8 | 28.7 | 21.1 | 69.1 | 13.0 | |
| 764.6 | 15,021.4 | 7,266.8 | 627.5 | 11.9 | 12.6 | 23.9 | 2.8 | |
| 362.9 | 13,894.8 | 2,051.5 | 180.5 | 11.6 | 7.7 | 68.9 | 3.6 | |
| 672.8 | 16,680.5 | 5,092.5 | 545.5 | 15.9 | 14.1 | 30.6 | 3.8 | |
| 1,071.0 | 19,182.7 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.3 | 2.2 | |
| 1,611.0 | 18,467.8 | 1,419.3 | 20.1 | 8.4 | 0.5 | 918.7 | 3.2 | |
| 153.8 | 20,457.1 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.6 | |
| 436.0 | 17,562.1 | 3,720.2 | 352.1 | 13.7 | 8.2 | 49.9 | 3.7 | |
| 1,450.3 | 23,577.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1071.7 | 5.1 |
No Review & Analysis are available.
Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active... pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acidic and allied products comprising sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India. Read more
Incorporated
2019
Chairman
Rashesh C Gogri
Managing Director
Narendra J Salvi
Headquarters
Vapi, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Aarti Pharmalabs Ltd is ₹693.95 (NSE) and ₹692.95 (BSE) as of 22-Apr-2026 IST. Aarti Pharmalabs Ltd has given a return of 23.96% in the last 3 years.
The P/E ratio of Aarti Pharmalabs Ltd is 29.39 times as on 22-Apr-2026, a 41 discount to its peers’ median range of 49.80 times.
The P/B ratio of Aarti Pharmalabs Ltd is 3.01 times as on 22-Apr-2026, a 9 discount to its peers’ median range of 3.31 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
24.91
|
3.41
|
|
2024
|
18.18
|
2.24
|
|
2023
|
12.86
|
1.60
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Aarti Pharmalabs Ltd are Rs 971.00 and Rs 585.00 as of 22-Apr-2026.
Aarti Pharmalabs Ltd has a market capitalisation of ₹ 6,282 Cr as on 22-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Aarti Pharmalabs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.